A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report

A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report

The outcome of patients with recurrent/metastatic cervical cancer (R/M CC) is poor, with a 5-year survival rate of only 10%–20%. Recent advances in immunotherapy renewed its interest in R/M CC treatment. It has been suggested that cadonilimab, a novel bispecific antibody targeting programmed death 1...

Full description

Saved in:

Bibliographic Details
Main Authors:	Haijuan Yu, Jie Lin, Jian Chen, Lijun Chen, Jianping Zou, Bin Liu, Dan Hu, Youping Xiao, Linhao Yu, Yang Sun
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Immunology
Subjects:	cadonilimab recurrent and/or metastatic cervical cancer complete response HER-2 case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1494138/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration
by: Du Feng, et al.
Published: (2024-12-01)

Combination of trastuzumab and pertuzumab with FOLFOXIRI as the neoadjuvant therapeutic tegimen for HER2-positive resectable metastatic colorectal cancer: The first case report
by: Hua-Yang Pang, et al.
Published: (2025-01-01)

The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study
by: Hongxin Li, et al.
Published: (2024-11-01)

Case report: Complete response in TMB-H advanced uterine clear cell carcinoma: a case analysis of paclitaxel albumin-bound combined with PD-1/CTLA-4 bispecific antibody
by: Yue Chen, et al.
Published: (2024-12-01)

Long lasting complete regression of a metastatic polyomavirus-positive Merkel cell carcinoma after COVID-19 booster vaccination
by: Ulrich Wesselmann, et al.
Published: (2024-12-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01)

Unveiling the natural history of paralysis in metastatic cervical spinal tumor: An experimental study
by: Shunsuke Sato, et al.
Published: (2024-01-01)

Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment
by: Laura Sun, et al.
Published: (2024-12-01)

Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US
by: Yingtao Lin, et al.
Published: (2024-11-01)

Dynamic changes in serum adenosine and the adenosine metabolism-based signature for prognosis in HER2-positive metastatic breast cancer patients
by: Lijun Wang, et al.
Published: (2024-12-01)

Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study
by: Yan Chen, et al.
Published: (2024-12-01)

Case report: Cutaneous metastasis of squamous cervical carcinoma: complete regression after molecular diagnosis
by: Liwen Guo, et al.
Published: (2025-01-01)

Indian clinical practice consensus guidelines for the management of recurrent, persistent, or metastatic squamous cell carcinoma of head-and-neck - Update 2023
by: Vanita Noronha, et al.
Published: (2024-11-01)

Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01)

The Second Incisional Site Metastasis in a Patient with Cervical Carcinoma: A Case Report
by: İpek Düzgüner, et al.
Published: (2013-12-01)

Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials
by: Shihui Hu, et al.
Published: (2024-11-01)

Treatment of metastatic breast cancer by stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS)
by: Xiaomin Li, et al.
Published: (2024-12-01)

The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by: Lu Li, et al.
Published: (2024-07-01)

Development and validation of a nomogram to predict recurrence in epithelial ovarian cancer using complete blood count and lipid profiles
by: Xi Tang, et al.
Published: (2025-02-01)

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by: Lu Li, et al.
Published: (2024-11-01)

The Association Between D-Dimer Levels and Recurrence in Patients with Early-Stage Cervical Cancer after Surgical Treatment
by: Chen Q, et al.
Published: (2024-12-01)

Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
by: Yanxiong Mao, et al.
Published: (2024-11-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Bidirectional recurrent neural network approach for predicting cervical cancer recurrence and survival
by: S. Geeitha, et al.
Published: (2024-12-01)

Double trouble: how c-MET and HER2 fuel bladder cancer progression
by: E. M. Naguib, et al.
Published: (2024-12-01)

Analysis of the implementation value of abdominal B-ultrasound combined with cervical cerclage in the prevention and treatment of late recurrent spontaneous abortion
by: Lili Shi, et al.
Published: (2024-12-01)

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01)

Cervical length of preoperative cervical cerclage prognostic impacted the effect of cervical insufficiency
by: Yayun Zhang, et al.
Published: (2025-01-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Multi-stage refinement network for point cloud completion based on geodesic attention
by: Yuchen Chang, et al.
Published: (2025-01-01)

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors
by: Neha Pathak, et al.
Published: (2025-01-01)

p-regular Cauchy completions
by: Darrell C. Kent, et al.
Published: (2000-01-01)

Complete mole coexisting with a normal fetus in a dichorionic diamniotic pregnancy: a case report
by: Maryanne Mwangi, et al.
Published: (2024-11-01)

Cervical cerclage vs cervical pessary in women with cervical insufficiency: A multicentric, open-label, randomised, controlled pilot trial [the CEPEIC trial]
by: Andrea Gascón, et al.
Published: (2024-12-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Zoledronic-acid plus neoadjuvant therapy is associated with provoking outcomes in Her2-positive breast cancer
by: Bruno de Paula, et al.
Published: (2025-01-01)

Investigating the impact of persistent HPV infection on recurrence of lesions post-surgery for early-stage cervical cancer and related influencing factors
by: Jing Na, et al.
Published: (2025-02-01)

Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer
by: Joshua Mangerel, MD, et al.
Published: (2025-03-01)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01)

Metastatic adenocarcinoma of the mandible–a rare entity
by: SH Hashmi, et al.
Published: (2011-10-01)